Charlene McDanal

11.9k total citations · 4 hit papers
24 papers, 3.6k citations indexed

About

Charlene McDanal is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Charlene McDanal has authored 24 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Virology, 12 papers in Infectious Diseases and 10 papers in Immunology. Recurrent topics in Charlene McDanal's work include HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (9 papers) and Immune Cell Function and Interaction (7 papers). Charlene McDanal is often cited by papers focused on HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (9 papers) and Immune Cell Function and Interaction (7 papers). Charlene McDanal collaborates with scholars based in United States, Italy and South Korea. Charlene McDanal's co-authors include Thomas J. Matthews, Carl Wild, A J Langlois, D C Shugars, Dani P. Bolognesi, Kashi Javaherian, J R Rusche, Terrence G. Oas, D P Bolognesi and L O Arthur and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Charlene McDanal

23 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

1994 804 citations Carl Wild, Charlene McDanal et al. Proceedings of the National Academy of Sciences profile →
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

1988 568 citations J R Rusche, Kashi Javaherian et al. Proceedings of the National Academy of Sciences profile →
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

1989 538 citations Kashi Javaherian, A J Langlois et al. Proceedings of the National Academy of Sciences profile →
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

2021 222 citations Xiaoying Shen, Haili Tang et al. Cell Host & Microbe profile →

Peers

Countries citing papers authored by Charlene McDanal

Since Specialization

Citations

This map shows the geographic impact of Charlene McDanal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene McDanal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene McDanal more than expected).

Fields of papers citing papers by Charlene McDanal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene McDanal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene McDanal. The network helps show where Charlene McDanal may publish in the future.

Co-authorship network of co-authors of Charlene McDanal

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene McDanal. A scholar is included among the top collaborators of Charlene McDanal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene McDanal. Charlene McDanal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation 2021 ·Scientific Reports ·Yunda Huang, Oleg Borisov, Jia Jin Kee, Lindsay N. Carpp, Terri Wrin, (unknown), Marcella Sarzotti‐Kelsoe, Charlene McDanal, Amanda Eaton, Rolando Pajón, John Hural, Christine M. Posavad, Katherine Gill, Shelly Karuna, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert, Christos J. Petropoulos, David C. Montefiori	20
2	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines breakdown → 2021 ·Cell Host & Microbe ·Xiaoying Shen, Haili Tang, Charlene McDanal, Kshitij Wagh, Will Fischer, James Theiler, Hyejin Yoon, Dapeng Li, Barton F. Haynes, (unknown), S. Gnanakaran, Nicolas Hengartner, Rolando Pajón, Gale Smith, Gregory M. Glenn, Bette Korber, David C. Montefiori	222
3	SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines 2021 ·SSRN Electronic Journal ·Xiaoying Shen, Haili Tang, Charlene McDanal, Kshitij Wagh, Will Fischer, James Theiler, Hyejin Yoon, Dapeng Li, Barton F. Haynes, Kevin O. Saunders, S. Gnanakaran, Nicolas Hengartner, Rolando Pajón, Gale Smith, Filip Dubovsky, Gregory M. Glenn, Bette Korber, David C. Montefiori	0
4	Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms 2017 ·Bioorganic & Medicinal Chemistry Letters ·Jun Tang, Stacey A. Jones, Jerry Jeffrey, Sónia Miranda, Cristin M. Galardi, David M. Irlbeck, Kevin Brown, Charlene McDanal, Brian A. Johns	19
5	Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase 2016 ·PLoS Biology ·Kushol Gupta, (unknown), Scott Sherrill-Mix, Young Sun Hwang, Grant Eilers, Louis J. Taylor, Charlene McDanal, Ping Wang, (unknown), Robert T. Nolte, (unknown), Jerry Jeffrey, Gregory D. Van Duyne, Frederic D. Bushman	52
6	In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti‐HIV Activity of Aplaviroc 2008 ·The Journal of Clinical Pharmacology ·James F. Demarest, (unknown), Kathleen Schell, Shiro Shibayama, Charlene McDanal, Fang Lei, Kimberly K. Adkison, (unknown), Stephen C. Piscitelli	10
7	A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago 2000 ·Proceedings of the National Academy of Sciences ·Farley Cleghorn, Noreen Jack, Jean K. Carr, Robert J. Edwards, (unknown), Anne Sill, Charlene McDanal, (unknown), Damon H. Goodman, (unknown), Thomas R. OʼBrien, Kent J. Weinhold, C Bartholomew, William A. Blattner, Michael Greenberg	52
8	Herpesvirus Saimiri Transformation of HIV Type 1 Suppressive CD8 ⁺ Lymphocytes from an HIV Type 1-Infected Asymptomatic Individual 1998 ·AIDS Research and Human Retroviruses ·Simon F. Lacey, Kent J. Weinhold, Chin‐Ho Chen, Charlene McDanal, Coreen Oei, Michael Greenberg	17
9	Random Copolymers Containing Specific Ratios of Negatively Charged and Aromatic Amino Acids Bind V3 Disulfide Loop and Neutralize Diverse HIV Type 1 Isolates 1995 ·AIDS Research and Human Retroviruses ·Kashi Javaherian, Charlene McDanal	10
10	Induction of HIV Type 1 Neutralizing and env -CD4 Blocking Antibodies by Immunization with Genetically Engineered HIV Type 1-Like Particles Containing Unprocessed gp160 Glycoproteins 1995 ·AIDS Research and Human Retroviruses ·Benjamin Rovinski, (unknown), (unknown), (unknown), (unknown), Charles Sia, (unknown), Susan Zolla‐Pazner, (unknown), Thomas J. Matthews, Charlene McDanal, John R. Mascola, Michel Klein	19
11	A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion 1995 ·Journal of Virology ·Chen‐Hsin Chen, Thomas J. Matthews, Charlene McDanal, Dani P. Bolognesi, Michael Greenberg	146
12	Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. 1994 ·Proceedings of the National Academy of Sciences ·Carl Wild, J W Dubay, (unknown), T. Baird, Terrence G. Oas, Charlene McDanal, Eric Hunter, Thomas J. Matthews	180
13	Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. 1993 ·The Journal of Experimental Medicine ·Barton F. Haynes, L O Arthur, (unknown), Thomas J. Matthews, A J Langlois, T J Palker, Mary Kate Hart, Richard M. Scearce, Dawn Jones, Charlene McDanal	15
14	Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. 1993 ·The Journal of Immunology ·Barton F. Haynes, (unknown), A J Langlois, Dani P. Bolognesi, M B Gardner, T J Palker, Richard M. Scearce, Dawn Jones, M. Anthony Moody, Charlene McDanal, (unknown)	35
15	A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. 1992 ·Proceedings of the National Academy of Sciences ·Carl Wild, Terrence G. Oas, Charlene McDanal, Dani P. Bolognesi, Thomas J. Matthews	418
16	Alteration of HIV-1 Infectivity and Neutralization by a Single Amino Acid Replacement in the V3 Loop Domain 1991 ·AIDS Research and Human Retroviruses ·Lucinda A. Ivanoff, David J. Looney, Charlene McDanal, (unknown), Flossie Wong‐Staal, A J Langlois, Stephen R. Petteway, Thomas J. Matthews	82
17	Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. 1990 ·The Journal of Experimental Medicine ·F Celada, Caterina Cambiaggi, (unknown), Samuele E. Burastero, Timothy J. Gregory, Eric J. Patzer, Joanna C. Porter, Charlene McDanal, Thomas J. Matthews	58
18	Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. 1990 ·The Journal of Immunology ·Mary Kate Hart, T J Palker, Thomas J. Matthews, A J Langlois, Nicholas W. Lerche, (unknown), Richard M. Scearce, Charlene McDanal, D P Bolognesi, Barton F. Haynes	73
19	Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. breakdown → 1989 ·Proceedings of the National Academy of Sciences ·Kashi Javaherian, A J Langlois, Charlene McDanal, (unknown), (unknown), (unknown), Albert T. Profy, J R Rusche, D P Bolognesi, Scott D. Putney	538
20	Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. breakdown → 1988 ·Proceedings of the National Academy of Sciences ·J R Rusche, Kashi Javaherian, Charlene McDanal, (unknown), D L Lynn, R Grimaila, A J Langlois, Robert C. Gallo, L O Arthur, Peter J. Fischinger	568

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact